GLENMARK PHARMACEUTICALS Limited, an India-based pharmaceutical company headquartered in Mumbai with operations in over 77 countries worldwide, will officially launch its Jamaican operation tomorrow.
Mr. Suresh Kumar, country manager for Jamaica and the Caribbean says, "Glenmark has been operating in Jamaica for the past six months and so far we have obtained registration for 33 pharmaceutical products with seven others in the process of registration."
He says that within two years, Glenmark intends to have 50 products registered for use in Jamaica covering three therapeutic segments - dermatology, gynaecology and internal medicine - including drugs for diabetes and cardiology.
Kumar says Glenmark is the leading pharmaceutical company in India for its range of branded generic products for the treatment of dermatological conditions.
The company is focused on the manufacture and marketing of formulation products and active ingredients (API) in India as well as globally and enjoys a diversified and growing presence in regulated and developing international markets.
The pharmaceutical company employs in excess of 3,300 people across its global operations and its shares are listed on the two large Indian stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
Glenmark has been operating in the Caribbean for more than a decade with established markets in Trinidad and Tobago, the Eastern Caribbean, Barbados and Belize.
Glenmark products will be distributed in Jamaica by Inter-Commercial Distributors Limited. The launch will take place on May 24, at the Hilton Kingston Hotel at 7:00 p.m.
